BroadOak Capital Partners is a life sciences-focused boutique financial institution providing direct investment through BroadOak Asset Management and investment banking services through BroadOak Partners. The firm focuses on growth capital investments in life sciences tools, diagnostics, and biopharma services companies.
70% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $10.6M (across 8 rounds with reported amounts).
Portfolio
9
Fund Size
$200M
Top Stage
Series B
Last 12 Mo
1
Team
AD
Austin Duke
Managing Director
Portfolio Breakdown
Stage Distribution
Sector Distribution
Investment Activity
DealsAvg Round Size
Portfolio
10 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 Axol Bioscience | Unknown | $2.8M | Jan 2026 |
 Codis | Growth | — | Oct 2025 |
 KROMATID | Series C | $8M | Aug 2025 |
 PBS Biotech | Unknown | $22M | Jan 2023 |
| SSeqWell, Inc | Series C | $7M | Jan 2022 |
 Genomenon | Series B | $20M | Jan 2022 |
 Halo Labs | Series B | $5.6M | Jan 2019 |
 Quartzy | Series B | $17M | Jan 2016 |
| Quartzy | Series A | — | Jan 2013 |
| BBiocision | Growth | $2.5M | Dec 2012 |
Top Co-Investors
Y Combinator2 shared
Silicon Badia2 shared
SV Angel2 shared
Start Ventures2 shared
Avego Management, LLC1 shared
1315 Capital1 shared
Calculus Capital1 shared
YC Continuity1 shared
Khosla Ventures1 shared
A Capital1 shared
A.Capital Ventures1 shared
Beringea1 shared
Red Cedar Ventures1 shared
Invest Detroit1 shared
Spring Mountain Capital1 shared
University of Michigan1 shared
Green Park & Golf Ventures1 shared
IrishAngels1 shared
Michigan Rise1 shared
Last updated: 20 October 2026